Top Page
TuHURA Biosciences
(NASDAQ:HURA)
TuHURA Biosciences (HURA) vs. SPDR S&P 500 ETF (SPY)
TuHURA Biosciences Business Overview & Revenue Model
TuHURA Biosciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -17.64K | -116.71K | 0.00 | 0.00 | 0.00 | -32.00K |
| EBITDA | -17.16M | -17.43M | -29.12M | -9.56M | -6.01M | -38.15M |
| Net Income | -15.52M | -21.68M | -29.32M | -9.37M | -7.02M | -38.30M |
Balance Sheet | ||||||
| Total Assets | 34.62M | 19.97M | 4.36M | 15.20M | 6.40M | 13.54M |
| Cash, Cash Equivalents and Short-Term Investments | 8.51M | 12.66M | 3.67M | 14.25M | 5.55M | 10.54M |
| Total Debt | 558.97K | 202.54K | 2.34M | 138.22K | 644.07K | 0.00 |
| Total Liabilities | 15.17M | 5.37M | 5.92M | 2.89M | 7.15M | 2.96M |
| Stockholders Equity | 19.45M | 14.59M | -1.56M | 12.30M | -747.82K | 10.58M |
Cash Flow | ||||||
| Free Cash Flow | -15.54M | -14.79M | -12.03M | -7.54M | -6.57M | -18.87M |
| Operating Cash Flow | -15.48M | -14.73M | -11.95M | -7.51M | -6.56M | -18.86M |
| Investing Cash Flow | -2.13M | -6.05M | -1.30M | -36.28K | -3.28K | 964.00K |
| Financing Cash Flow | 4.63M | 29.77M | 2.66M | 16.25M | 7.04M | 26.04M |
TuHURA Biosciences Technical Analysis
TuHURA Biosciences Risk Analysis
TuHURA Biosciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $77.07M | -0.46 | -209.00% | ― | ― | 40.22% | |
49 Neutral | $27.89M | -0.67 | -94.31% | ― | ― | -53.18% | |
47 Neutral | $114.73M | -0.65 | -328.45% | ― | -10.36% | 42.36% | |
47 Neutral | $90.92M | -2.17 | -109.73% | ― | ― | 50.39% | |
45 Neutral | $98.28M | -1.36 | ― | ― | -33.41% | 81.19% | |
41 Neutral | $28.16M | -0.71 | -418.06% | ― | ― | 99.21% |
TuHURA Biosciences Corporate Events
On January 29, 2026, TuHURA Biosciences disclosed that it had received a notice from Nasdaq stating that its common stock had closed below $1.00 per share for 35 consecutive business days as of January 28, 2026, placing the company out of compliance with the exchange’s minimum bid price rule for continued listing. The company has been granted an initial 180-calendar day grace period, until July 28, 2026, to restore compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days, with the possibility of an additional 180-day extension if certain other listing criteria are met and, if needed, a reverse stock split is pursued. While the notice does not immediately affect trading or SEC reporting requirements, continued non-compliance could ultimately lead to delisting proceedings, adding pressure on management to stabilize the share price and preserve the company’s Nasdaq listing status.
The most recent analyst rating on (HURA) stock is a Hold with a $0.54 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
On December 9, 2025, TuHURA Biosciences announced a securities purchase agreement with investors for a registered direct offering of 9,462,423 shares of common stock and accompanying warrants, expected to raise approximately $15.6 million in three tranches. The proceeds will be used for working capital, satisfying a $3.4 million bridge note obligation, and general corporate purposes, impacting the company’s financial operations and potentially strengthening its market position.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
TuHURA Biosciences, Inc. entered into a Secured Promissory Note and Loan Agreement with the Matthew Nachtrab Revocable Trust, initially securing a loan of $1.5 million with a total potential of $3.0 million. On December 2, 2025, the agreement was amended to extend the loan availability period and adjust the warrants issuable to the lender. Following this amendment, TuHURA borrowed an additional $1.5 million, reaching the full $3.0 million loan capacity, and issued warrants for 234,783 shares of common stock.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
On November 22, 2025, TuHURA Biosciences, Inc.’s Shelf Registration Statement became effective, allowing the company to continue offering shares previously registered under a Resale Registration Statement. This development enables the selling securityholders to offer shares from time to time under the new registration, potentially impacting the company’s market operations and investor relations.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
On June 30, 2025, TuHURA Biosciences completed its acquisition of Kineta, Inc., following a series of mergers that began with an agreement on December 11, 2024. This acquisition included the rights to Kineta’s novel antibody, TBS-2025, and was executed through a combination of cash and stock. The mergers were accounted for as a business combination under U.S. GAAP, and TuHURA has provided pro forma financial statements to reflect these transactions as if they had occurred on January 1, 2024. This strategic move is expected to enhance TuHURA’s market position and operational capabilities.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
On November 3, 2025, TuHURA Biosciences entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to potentially sell up to $50 million in common stock. The proceeds from this offering are intended for working capital and general corporate purposes, although there is no obligation to sell shares, and the agreement can be suspended or terminated by either party.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
In June 2025, TuHURA Biosciences initiated a Phase 3 trial for its lead product, IFx-2.0, as an adjunctive therapy to Keytruda in treating advanced Merkel cell carcinoma, aiming for accelerated FDA approval. Following its acquisition of Kineta, TuHURA plans a Phase 2 trial for TBS-2025, a VISTA-inhibiting antibody, in combination with a menin inhibitor for treating acute myeloid leukemia, potentially enhancing response rates and reducing relapse.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
On October 27, 2025, TuHURA Biosciences entered into a Secured Promissory Note and Loan Agreement with the Matthew Nachtrab Revocable Trust for a bridge loan of up to $3,000,000 to be used for working capital. The loan is secured by U.S. patents related to TuHURA’s ImmuneFxTM technology and includes the issuance of warrants to purchase common stock, reflecting a strategic move to bolster financial resources and potentially enhance its market position.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.